Limits...
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.

Fu L, Shi J, Hu K, Wang J, Wang W, Ke X - Oncotarget (2015)

Bottom Line: We found that MAPKBP1 was over-expressed in cytogenetically normal AML (CN-AML) patients compared to normal bone marrow.High MAPKBP1 expression (MAPKBP1high) was associated with significantly shorter event-free survival (EFS; P = 0.0004) and overall survival (OS; P = 0.0006) than low MAPKBP1 expression (MAPKBP1low) in a cohort of 157 CN-AML patients.In multivariable analyses, MAPKBP1high remained associated with shorter EFS (P = 0.003) and OS (P = 0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, China.

ABSTRACT
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is a key transcription factor in the NF-κB signalling pathway. In this study, associations between MAPKBP1 expression and molecular and clinical characteristics were evaluated by several microarray datasets. We found that MAPKBP1 was over-expressed in cytogenetically normal AML (CN-AML) patients compared to normal bone marrow. High MAPKBP1 expression (MAPKBP1high) was associated with significantly shorter event-free survival (EFS; P = 0.0004) and overall survival (OS; P = 0.0006) than low MAPKBP1 expression (MAPKBP1low) in a cohort of 157 CN-AML patients. In multivariable analyses, MAPKBP1high remained associated with shorter EFS (P = 0.003) and OS (P = 0.01). Validation in an independent cohort of 162 CN-AML patients further confirmed the prognostic value of MAPKBP1 (OS, P = 0.00172). Gene-expression profiling revealed that some important oncogenes, including MYCN, MYB, CDK6 and CCND2, etc, were up-regulated, while cell signalling pathways leading to apoptosis, antigen processing, and natural killer cell-mediated cytotoxicity were down-regulated in MAPKBP1high patients with CN-AML. MicroRNA expression profiling revealed thatsome oncogenic microRNAsincluding miR-155 and miR-126 were up-regulated, whilst anti-oncogenic microRNAsincluding miR-148a and miR-193a were down-regulated in MAPKBP1high patients with CN-AML, which may underlie the pathological processes in this malignancy. Taken together, these findings suggest MAPKBP1highis a novel, unfavourably prognostic biomarker for CN-AML risk-stratification.

No MeSH data available.


Related in: MedlinePlus

Associations of MAPKBP1 expression with clinical outcome in ELN genetic groups(A) EFS and (B) OS of CN-AML patients in the ELN favourably genetic group. (C) EFS and (D) OS of CN-AML patients in the ELN intermediate-I genetic group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4480741&req=5

Figure 3: Associations of MAPKBP1 expression with clinical outcome in ELN genetic groups(A) EFS and (B) OS of CN-AML patients in the ELN favourably genetic group. (C) EFS and (D) OS of CN-AML patients in the ELN intermediate-I genetic group.

Mentions: We analysed the associations between MAPKBP1 expression and outcome separately within the ELN favourable and Intermediate-I genetic groups. Within the ELN favourable group (n = 59), there was no significant difference in EFS (Figure 3A, P = 0.0899) and OS (Figure 3B, P = 0.1561) between MAPKBP1high group and MAPKBP1lowgroup. However, MAPKBP1high group tended to have shorter EFS and OS than MAPKBP1low group. In the ELN Intermediate-I group (n = 122), MAPKBP1high group had a shorter EFS (Figure 3C, P = 0.0073) and shorter OS (Figure 3D, P = 0.0086) than MAPKBP1low group. Median OS and EFS of different expressing divisions also showed a significant difference. (Table 2).


Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.

Fu L, Shi J, Hu K, Wang J, Wang W, Ke X - Oncotarget (2015)

Associations of MAPKBP1 expression with clinical outcome in ELN genetic groups(A) EFS and (B) OS of CN-AML patients in the ELN favourably genetic group. (C) EFS and (D) OS of CN-AML patients in the ELN intermediate-I genetic group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4480741&req=5

Figure 3: Associations of MAPKBP1 expression with clinical outcome in ELN genetic groups(A) EFS and (B) OS of CN-AML patients in the ELN favourably genetic group. (C) EFS and (D) OS of CN-AML patients in the ELN intermediate-I genetic group.
Mentions: We analysed the associations between MAPKBP1 expression and outcome separately within the ELN favourable and Intermediate-I genetic groups. Within the ELN favourable group (n = 59), there was no significant difference in EFS (Figure 3A, P = 0.0899) and OS (Figure 3B, P = 0.1561) between MAPKBP1high group and MAPKBP1lowgroup. However, MAPKBP1high group tended to have shorter EFS and OS than MAPKBP1low group. In the ELN Intermediate-I group (n = 122), MAPKBP1high group had a shorter EFS (Figure 3C, P = 0.0073) and shorter OS (Figure 3D, P = 0.0086) than MAPKBP1low group. Median OS and EFS of different expressing divisions also showed a significant difference. (Table 2).

Bottom Line: We found that MAPKBP1 was over-expressed in cytogenetically normal AML (CN-AML) patients compared to normal bone marrow.High MAPKBP1 expression (MAPKBP1high) was associated with significantly shorter event-free survival (EFS; P = 0.0004) and overall survival (OS; P = 0.0006) than low MAPKBP1 expression (MAPKBP1low) in a cohort of 157 CN-AML patients.In multivariable analyses, MAPKBP1high remained associated with shorter EFS (P = 0.003) and OS (P = 0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, China.

ABSTRACT
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is a key transcription factor in the NF-κB signalling pathway. In this study, associations between MAPKBP1 expression and molecular and clinical characteristics were evaluated by several microarray datasets. We found that MAPKBP1 was over-expressed in cytogenetically normal AML (CN-AML) patients compared to normal bone marrow. High MAPKBP1 expression (MAPKBP1high) was associated with significantly shorter event-free survival (EFS; P = 0.0004) and overall survival (OS; P = 0.0006) than low MAPKBP1 expression (MAPKBP1low) in a cohort of 157 CN-AML patients. In multivariable analyses, MAPKBP1high remained associated with shorter EFS (P = 0.003) and OS (P = 0.01). Validation in an independent cohort of 162 CN-AML patients further confirmed the prognostic value of MAPKBP1 (OS, P = 0.00172). Gene-expression profiling revealed that some important oncogenes, including MYCN, MYB, CDK6 and CCND2, etc, were up-regulated, while cell signalling pathways leading to apoptosis, antigen processing, and natural killer cell-mediated cytotoxicity were down-regulated in MAPKBP1high patients with CN-AML. MicroRNA expression profiling revealed thatsome oncogenic microRNAsincluding miR-155 and miR-126 were up-regulated, whilst anti-oncogenic microRNAsincluding miR-148a and miR-193a were down-regulated in MAPKBP1high patients with CN-AML, which may underlie the pathological processes in this malignancy. Taken together, these findings suggest MAPKBP1highis a novel, unfavourably prognostic biomarker for CN-AML risk-stratification.

No MeSH data available.


Related in: MedlinePlus